WO2022127261A1 - 一种化合物及其制备方法以及其在制备治疗抗癌药物中的应用 - Google Patents
一种化合物及其制备方法以及其在制备治疗抗癌药物中的应用 Download PDFInfo
- Publication number
- WO2022127261A1 WO2022127261A1 PCT/CN2021/120046 CN2021120046W WO2022127261A1 WO 2022127261 A1 WO2022127261 A1 WO 2022127261A1 CN 2021120046 W CN2021120046 W CN 2021120046W WO 2022127261 A1 WO2022127261 A1 WO 2022127261A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- preparation
- nmr
- pharmaceutically acceptable
- formula
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 179
- 150000001875 compounds Chemical class 0.000 title claims abstract description 117
- 239000002246 antineoplastic agent Substances 0.000 title abstract description 6
- 229940041181 antineoplastic drug Drugs 0.000 title abstract description 5
- 230000001225 therapeutic effect Effects 0.000 title abstract description 3
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 40
- 201000011510 cancer Diseases 0.000 claims abstract description 20
- 108091008794 FGF receptors Proteins 0.000 claims description 38
- 210000004881 tumor cell Anatomy 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 18
- 229940125773 compound 10 Drugs 0.000 claims description 14
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 claims description 12
- 229940125878 compound 36 Drugs 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 239000003112 inhibitor Substances 0.000 claims description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 6
- 230000002159 abnormal effect Effects 0.000 claims description 6
- 230000019491 signal transduction Effects 0.000 claims description 6
- 238000006069 Suzuki reaction reaction Methods 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 5
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 238000006751 Mitsunobu reaction Methods 0.000 claims description 4
- 238000005917 acylation reaction Methods 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 229910052786 argon Inorganic materials 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 238000010511 deprotection reaction Methods 0.000 claims description 4
- 239000007928 intraperitoneal injection Substances 0.000 claims description 4
- 230000004663 cell proliferation Effects 0.000 claims description 3
- 230000002427 irreversible effect Effects 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 2
- 230000000903 blocking effect Effects 0.000 claims description 2
- 239000003560 cancer drug Substances 0.000 claims description 2
- 229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 230000001028 anti-proliverative effect Effects 0.000 abstract description 3
- -1 pyrazolo[3,4-d]pyrimidine compound Chemical class 0.000 abstract 1
- 238000005481 NMR spectroscopy Methods 0.000 description 121
- 238000012360 testing method Methods 0.000 description 45
- 239000002994 raw material Substances 0.000 description 39
- 229940125904 compound 1 Drugs 0.000 description 37
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 30
- 239000000243 solution Substances 0.000 description 23
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 15
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 15
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 230000007783 downstream signaling Effects 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 10
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 10
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 9
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 8
- HXRDRJKAEYHOBB-UHFFFAOYSA-N tert-butyl 3-(hydroxymethyl)azetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(CO)C1 HXRDRJKAEYHOBB-UHFFFAOYSA-N 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 239000006180 TBST buffer Substances 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 4
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 4
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 4
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 4
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 3
- VREWSCMOGIXMDQ-UHFFFAOYSA-N (2,3-dimethoxyphenyl)boronic acid Chemical compound COC1=CC=CC(B(O)O)=C1OC VREWSCMOGIXMDQ-UHFFFAOYSA-N 0.000 description 3
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 3
- QUKPALAWEPMWOS-UHFFFAOYSA-N 1h-pyrazolo[3,4-d]pyrimidine Chemical class C1=NC=C2C=NNC2=N1 QUKPALAWEPMWOS-UHFFFAOYSA-N 0.000 description 3
- QZBAYURFHCTXOJ-UHFFFAOYSA-N 4,4,4-trifluorobut-2-enoic acid Chemical compound OC(=O)C=CC(F)(F)F QZBAYURFHCTXOJ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 3
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 3
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 229940125877 compound 31 Drugs 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 3
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- ROEQGIFOWRQYHD-UHFFFAOYSA-N (2-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC=C1B(O)O ROEQGIFOWRQYHD-UHFFFAOYSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 2
- QWQBQRYFWNIDOC-UHFFFAOYSA-N (3,5-difluorophenyl)boronic acid Chemical compound OB(O)C1=CC(F)=CC(F)=C1 QWQBQRYFWNIDOC-UHFFFAOYSA-N 0.000 description 2
- XUIURRYWQBBCCK-UHFFFAOYSA-N (3,5-dimethoxyphenyl)boronic acid Chemical compound COC1=CC(OC)=CC(B(O)O)=C1 XUIURRYWQBBCCK-UHFFFAOYSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 2
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- VRQMAABPASPXMW-HDICACEKSA-N AZD4547 Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(=CC=3)N3C[C@@H](C)N[C@@H](C)C3)C=2)=C1 VRQMAABPASPXMW-HDICACEKSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- 229940126639 Compound 33 Drugs 0.000 description 2
- 229940127007 Compound 39 Drugs 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- YJVBLROMQZEFPA-UHFFFAOYSA-L acid red 26 Chemical compound [Na+].[Na+].CC1=CC(C)=CC=C1N=NC1=C(O)C(S([O-])(=O)=O)=CC2=CC(S([O-])(=O)=O)=CC=C12 YJVBLROMQZEFPA-UHFFFAOYSA-L 0.000 description 2
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- XTEOJPUYZWEXFI-UHFFFAOYSA-N butyl n-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC XTEOJPUYZWEXFI-UHFFFAOYSA-N 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 229940127204 compound 29 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125807 compound 37 Drugs 0.000 description 2
- 229940127573 compound 38 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- VQSRKMNBWMHJKY-YTEVENLXSA-N n-[3-[(4ar,7as)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-methoxypyrazine-2-carboxamide Chemical compound C1=NC(OC)=CN=C1C(=O)NC1=CC=C(F)C([C@@]23[C@@H](CN(C2)C=2N=CC(F)=CN=2)CSC(N)=N3)=C1 VQSRKMNBWMHJKY-YTEVENLXSA-N 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QOZLFNQLIKOGDR-UHFFFAOYSA-N (2,5-dimethoxyphenyl)boronic acid Chemical compound COC1=CC=C(OC)C(B(O)O)=C1 QOZLFNQLIKOGDR-UHFFFAOYSA-N 0.000 description 1
- REFXAANPQCJZRY-UHFFFAOYSA-N (2-chloro-5-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(Cl)C(B(O)O)=C1 REFXAANPQCJZRY-UHFFFAOYSA-N 0.000 description 1
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 1
- RULQUTYJXDLRFL-UHFFFAOYSA-N (3,4,5-trimethoxyphenyl)boronic acid Chemical compound COC1=CC(B(O)O)=CC(OC)=C1OC RULQUTYJXDLRFL-UHFFFAOYSA-N 0.000 description 1
- RCVDPBFUMYUKPB-UHFFFAOYSA-N (3,4-dimethoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1OC RCVDPBFUMYUKPB-UHFFFAOYSA-N 0.000 description 1
- OYNDLOJPYURCJG-UHFFFAOYSA-N (3-fluoro-4-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=C(O)C(F)=C1 OYNDLOJPYURCJG-UHFFFAOYSA-N 0.000 description 1
- MQFKLCWETPKBCH-UHFFFAOYSA-N (3-fluoro-5-methoxyphenyl)boronic acid Chemical compound COC1=CC(F)=CC(B(O)O)=C1 MQFKLCWETPKBCH-UHFFFAOYSA-N 0.000 description 1
- WIJNYNBSPQMJGO-UHFFFAOYSA-N (3-phenylmethoxyphenyl)boronic acid Chemical compound OB(O)C1=CC=CC(OCC=2C=CC=CC=2)=C1 WIJNYNBSPQMJGO-UHFFFAOYSA-N 0.000 description 1
- UKZVUHVNTYDSOP-UHFFFAOYSA-N (3-propan-2-yloxyphenyl)boronic acid Chemical compound CC(C)OC1=CC=CC(B(O)O)=C1 UKZVUHVNTYDSOP-UHFFFAOYSA-N 0.000 description 1
- VYEWTHXZHHATTA-UHFFFAOYSA-N (4-acetamidophenyl)boronic acid Chemical compound CC(=O)NC1=CC=C(B(O)O)C=C1 VYEWTHXZHHATTA-UHFFFAOYSA-N 0.000 description 1
- JHVQEUGNYSVSDH-UHFFFAOYSA-N (4-methylnaphthalen-1-yl)boronic acid Chemical compound C1=CC=C2C(C)=CC=C(B(O)O)C2=C1 JHVQEUGNYSVSDH-UHFFFAOYSA-N 0.000 description 1
- NSFJAFZHYOAMHL-UHFFFAOYSA-N (4-nitrophenyl)boronic acid Chemical compound OB(O)C1=CC=C([N+]([O-])=O)C=C1 NSFJAFZHYOAMHL-UHFFFAOYSA-N 0.000 description 1
- GZFAVYWCPSMLCM-UHFFFAOYSA-N (6-methoxynaphthalen-2-yl)boronic acid Chemical compound C1=C(B(O)O)C=CC2=CC(OC)=CC=C21 GZFAVYWCPSMLCM-UHFFFAOYSA-N 0.000 description 1
- ITGIYLMMAABTHC-ONEGZZNKSA-N (e)-4-(dimethylazaniumyl)but-2-enoate Chemical compound CN(C)C\C=C\C(O)=O ITGIYLMMAABTHC-ONEGZZNKSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- SWLIDGUINRBEFI-UHFFFAOYSA-N 3-bicyclo[4.1.0]hepta-1(6),2,4-trienylboronic acid Chemical compound C1C=2C=C(C=CC=21)B(O)O SWLIDGUINRBEFI-UHFFFAOYSA-N 0.000 description 1
- GZQVGSRUUTUJNG-UHFFFAOYSA-N 3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound NC1=NC=NC2=NNC(Br)=C12 GZQVGSRUUTUJNG-UHFFFAOYSA-N 0.000 description 1
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 1
- VJOWMORERYNYON-UHFFFAOYSA-N 5-ethenyl-2-methylpyridine Chemical compound CC1=CC=C(C=C)C=N1 VJOWMORERYNYON-UHFFFAOYSA-N 0.000 description 1
- BIAPRCBXKMQPEK-UHFFFAOYSA-N B(O)O.BrC1=CC=CC2=CC=CC=C12 Chemical compound B(O)O.BrC1=CC=CC2=CC=CC=C12 BIAPRCBXKMQPEK-UHFFFAOYSA-N 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- QADPYRIHXKWUSV-UHFFFAOYSA-N BGJ-398 Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1NC1=CC(N(C)C(=O)NC=2C(=C(OC)C=C(OC)C=2Cl)Cl)=NC=N1 QADPYRIHXKWUSV-UHFFFAOYSA-N 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- CUDVHEFYRIWYQD-UHFFFAOYSA-N E-3810 free base Chemical compound C=1C=C2C(C(=O)NC)=CC=CC2=CC=1OC(C1=CC=2OC)=CC=NC1=CC=2OCC1(N)CC1 CUDVHEFYRIWYQD-UHFFFAOYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102100031734 Fibroblast growth factor 19 Human genes 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 101000846394 Homo sapiens Fibroblast growth factor 19 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- BPTABBGLHGBJQR-UHFFFAOYSA-N [3,5-bis(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 BPTABBGLHGBJQR-UHFFFAOYSA-N 0.000 description 1
- WOAORAPRPVIATR-UHFFFAOYSA-N [3-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC(C(F)(F)F)=C1 WOAORAPRPVIATR-UHFFFAOYSA-N 0.000 description 1
- WEMCWZGCSRGJGW-UHFFFAOYSA-N [3-fluoro-5-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC(F)=CC(C(F)(F)F)=C1 WEMCWZGCSRGJGW-UHFFFAOYSA-N 0.000 description 1
- HUOFUOCSQCYFPW-UHFFFAOYSA-N [4-(trifluoromethoxy)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(OC(F)(F)F)C=C1 HUOFUOCSQCYFPW-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- PIQCTGMSNWUMAF-UHFFFAOYSA-N chembl522892 Chemical compound C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C(NC4=CC=CC(F)=C4C=3N)=O)C2=C1 PIQCTGMSNWUMAF-UHFFFAOYSA-N 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229950004444 erdafitinib Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- CPMDPSXJELVGJG-UHFFFAOYSA-N methyl 2-hydroxy-3-[N-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylate Chemical compound OC=1NC2=CC(=CC=C2C=1C(=NC1=CC=C(C=C1)N(C(CN1CCN(CC1)C)=O)C)C1=CC=CC=C1)C(=O)OC CPMDPSXJELVGJG-UHFFFAOYSA-N 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- OLAHOMJCDNXHFI-UHFFFAOYSA-N n'-(3,5-dimethoxyphenyl)-n'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-n-propan-2-ylethane-1,2-diamine Chemical compound COC1=CC(OC)=CC(N(CCNC(C)C)C=2C=C3N=C(C=NC3=CC=2)C2=CN(C)N=C2)=C1 OLAHOMJCDNXHFI-UHFFFAOYSA-N 0.000 description 1
- KPTRDYONBVUWPD-UHFFFAOYSA-N naphthalen-2-ylboronic acid Chemical compound C1=CC=CC2=CC(B(O)O)=CC=C21 KPTRDYONBVUWPD-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- OJCLHERKFHHUTB-UHFFFAOYSA-N tert-butyl 3-(hydroxymethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(CO)C1 OJCLHERKFHHUTB-UHFFFAOYSA-N 0.000 description 1
- HKIGXXRMJFUUKV-UHFFFAOYSA-N tert-butyl 3-(hydroxymethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CO)C1 HKIGXXRMJFUUKV-UHFFFAOYSA-N 0.000 description 1
- VRXIOAYUQIITBU-UHFFFAOYSA-N tert-butyl 4-(2-hydroxyethyl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(CCO)CC1 VRXIOAYUQIITBU-UHFFFAOYSA-N 0.000 description 1
- YBNJZIDYXCGAPX-UHFFFAOYSA-N tert-butyl 4-(2-hydroxyethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CCO)CC1 YBNJZIDYXCGAPX-UHFFFAOYSA-N 0.000 description 1
- CTEDVGRUGMPBHE-UHFFFAOYSA-N tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CO)CC1 CTEDVGRUGMPBHE-UHFFFAOYSA-N 0.000 description 1
- PWQLFIKTGRINFF-UHFFFAOYSA-N tert-butyl 4-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)CC1 PWQLFIKTGRINFF-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the invention relates to the technical field of pharmacy, in particular to 2H-pyrazolo[3,4-d]pyrimidine derivatives and a preparation method thereof and their application in the preparation of anticancer drugs.
- Fibroblast growth factor receptor is a member of the receptor tyrosine kinase (RTK) family and belongs to the receptor-type protein tyrosine kinase, which contains four highly conserved transmembrane tyrosine kinases: FGFR1, FGFR2 , FGFR3 and FGFR4.
- the signaling pathway of FGFR is that ligand-receptor binding induces FGFR dimerization, which leads to cascade activation of downstream signaling pathways such as Ras-MAPK, PI3K-Akt, STAT and PLC ⁇ .
- FGFRs play important roles in a variety of cellular functions, such as cell proliferation and differentiation, and biological processes including development, angiogenesis, homeostasis, and wound repair. According to research surveys (1-3) , 7.1% of cancer patients have abnormal FGFR. For example, FGFR1 amplification was highest in patients with squamous NSCLC at 20%, breast cancer at 10%, ovarian cancer at 5%, and bladder cancer at 3%.
- FGFR2 mutations have been identified in gastric cancer (10%), endometrial cancer (12%), squamous NSCLC (5%) and triple-negative breast cancer (4%), while FGFR3 mutations in bladder cancer (50-60%) and myeloma (15-20%) are well known.
- FGFR inhibitors as novel anticancer agents for the treatment of FGFR-related cancers.
- TKIs multi-targeted tyrosine kinase inhibitors
- FGFR abnormalities such as dovitinib (TKI-258), lucitanib (E-3810) (8) , nintedanib (BIBF-1120) (9) , and ponatinib (AP-24534) (10) .
- FGFR inhibitors were non-selective (11) .
- FGFR tyrosine kinase inhibitors with various scaffolds have been developed.
- tyrosine kinase inhibitors are currently in various stages of clinical studies, such as AZD-4547 (Phase III) (12) , BGJ-398 (Phase II) (13) , LY-2874455 (Phase II) (14) and JNJ-42756493 (Phase II) (15) , these selective FGFR inhibitors are ATP-competitive inhibitors that bind to the active form of FGFR.
- FGFR inhibitors are ATP-competitive inhibitors that bind to the active form of FGFR.
- many medicinal chemistry laboratories have reported their development of FGFR inhibitors (16-22) .
- the technical problems to be solved/objects achieved by the present invention at least include: overcoming the defects in the prior art, proposing 2H-pyrazolo[3,4-d]pyrimidine derivatives and their preparation methods, and their use in the preparation of anticancer drugs applications in .
- the present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof:
- Ar is any one of a substituted aromatic ring group and a substituted aromatic heterocyclic group
- R is any one of H, alkyl, aryl, -CF and alkyl tertiary amine structures
- Linker is any one of an alkyl group, an alkoxy group, a heteroatom substituent, and a substituted N heterocyclic ring.
- the Ar is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- the R is H, CF 3 , (CH 3 ) 2 NCH 2 or CH 3 .
- the compound is one of compounds 1 to 40:
- the present invention also provides the preparation method of the compound described in the above-mentioned technical scheme or its pharmaceutically acceptable salt, and its synthetic route is:
- the compound with the structure shown in formula a and the compound with the structure shown in formula b are subjected to Mitsunobu reaction to obtain the compound with the structure shown in formula c;
- the temperature of the Mitsunobu reaction is room temperature, and the time is 4h;
- the Suzuki coupling (Suzuki coupling) reaction is performed on the compound with the structure shown in the formula c and the compound with the structure shown in the formula d to obtain the compound with the structure shown in the formula e; the temperature of the Suzuki coupling reaction is 80 ° C;
- Deprotection reaction of the compound with the structure represented by the formula e and trifluoroacetic acid is carried out to obtain the compound with the structure represented by the formula f; the temperature of the deprotection reaction is 0°C;
- the acylation reaction of the compound with the structure shown in formula f is carried out to obtain the compound with the structure shown in the formula I; the temperature of the acylation reaction is room temperature;
- the present invention also provides the application of the compound described in the above technical solution and a pharmaceutically acceptable salt thereof in the preparation of a tumor cell proliferation inhibitor, wherein the tumor cell is a related tumor cell with abnormal FGFR.
- the tumor cells include NCI-H1581 or SNU-16.
- the present invention also provides the use of the compounds described in the above technical solutions and their pharmaceutically acceptable salts in blocking the FGF/FGFR signaling pathway in tumor cells, which are related tumor cells with abnormal FGFR.
- the tumor cells include NCI-H1581 or SNU-16.
- the present invention also provides a pharmaceutical composition containing the compound described in the above technical solution and a pharmaceutically acceptable salt thereof, including one or more pharmaceutically acceptable excipients;
- the dosage form of the pharmaceutical composition is any pharmaceutically acceptable dosage form.
- the present invention also provides the application of the compound described in the above technical solution, a pharmaceutically acceptable salt thereof or the pharmaceutical composition described in the above technical solution in preparing a medicine for treating and/or preventing cancer.
- the cancer is a related cancer with FGFR abnormalities.
- the present invention also provides the application of the pharmaceutical composition described in the above technical scheme for preparing an irreversible pan-fibroblast growth factor receptor inhibitor.
- the present invention also provides a method for treating cancer, comprising the following steps:
- the drugs for treating cancer include the compounds described in the above technical solutions, and pharmaceutically acceptable salts thereof.
- the drug for treating cancer includes compound 10 or compound 36.
- the administered dose is 50 mg/kg or 100 mg/kg;
- the administered dose is based on the amount of the compound 10 or compound 36.
- the mode of administration is oral.
- the mode of administration is intraperitoneal injection.
- pharmaceutically acceptable adjuvant includes pharmaceutically acceptable carriers, excipients, diluents, etc., which are compatible with the active pharmaceutical ingredients.
- pharmaceutically acceptable carriers include pharmaceutically acceptable carriers, excipients, diluents, etc., which are compatible with the active pharmaceutical ingredients.
- the preparation of pharmaceutical formulations using pharmaceutically acceptable excipients is well known to those of ordinary skill in the art.
- the present invention combines the pharmaceutical composition and pharmaceutically acceptable adjuvants (such as carriers, excipients, diluents, etc. well known to those of ordinary skill in the art) to prepare various preparations, preferably solid preparations and liquid preparations
- adjuvants such as carriers, excipients, diluents, etc. well known to those of ordinary skill in the art
- various preparations preferably solid preparations and liquid preparations
- Formulations such as tablets, pills, capsules, powders, suspensions, granules, syrups, emulsions, suspensions, etc., as well as various sustained-release dosage forms, are preferably in the form of oral administration.
- Figure 1 shows that compound 10 inhibits the activation of FGFR1 and downstream signaling pathways in NCI-H1581 cells and inhibits the activation of FGFR2 and downstream signaling pathways in SNU-16 cells in a concentration-dependent manner, wherein A is the inhibition of FGFR1 and downstream signaling pathways in NCI-H1581 cells Activation of signaling pathways, B is to inhibit the activation of FGFR2 and downstream signaling pathways in SNU-16 cells;
- Figure 2 shows that compound 36 concentration-dependently inhibits the activation of FGFR1 and downstream signaling pathways in NCI-H1581 cells and inhibits the activation of FGFR2 and downstream signaling pathways in SUN-16 cells, wherein A is the inhibition of FGFR1 and downstream signaling pathways in NCI-H1581 cells Activation of signaling pathways, B is to inhibit the activation of FGFR2 and downstream signaling pathways in SUN-16 cells;
- Figure 3 shows the tumor volume curve graph (A) of compound 10 inhibiting tumor proliferation in the subcutaneous transplanted tumor model of NCI-H1581 tumor cells, the tumor tumor weight statistics graph (B) in mice after 26 days of treatment, and the body weight of mice during the treatment process.
- Figure 4 is a graph showing the tumor volume change curve (A) of compound 36 inhibiting tumor proliferation in the subcutaneous transplanted tumor model of NCI-H1581 tumor cells (A), a statistical graph of tumor tumor weight in mice after 26 days of treatment (B), and the mice during the treatment process.
- test reagents used in the following examples are conventional biochemical reagents unless otherwise specified; the experimental methods are conventional methods unless otherwise specified.
- the specific preparation method is:
- reaction was continued for 1 h at room temperature, and the completion of the reaction was monitored by TLC.
- the specific preparation method is: similar to the preparation method of compound 1, except that one of the raw materials used is 1-Boc-3-hydroxymethylpyrrolidine, and equimolar replaces 1 in the preparation method of compound (1-1).
- -Boc-3-azetidine methanol the NMR test results of compound 2 are:
- the specific preparation method is: similar to the preparation method of compound 1, except that one of the raw materials used is N-Boc-4-hydroxypiperidine, and equimolar replaces 1-Boc in the preparation method of compound (1-1). -3-azetidine methanol, the NMR test results of compound 3 are:
- the specific preparation method is: similar to the preparation method of compound 1, except that one of the raw materials used is N-Boc-4-piperidinemethanol, and equimolar replaces 1-Boc in the preparation method of compound (1-1). -3-azetidine methanol, the NMR test results of compound 4 are:
- the specific preparation method is: similar to the preparation method of compound 1, the difference is that one of the raw materials used is N-Boc-4-piperidineethanol, and equimolar replaces 1-Boc in the preparation method of compound (1-1). -3-azetidine methanol, the NMR test results of compound 5 are:
- the specific preparation method is: similar to the preparation method of compound 1, except that one of the raw materials used is 1-Boc-3-hydroxymethylpiperidine, and equimolar replaces 1 in the preparation method of compound (1-1).
- -Boc-3-azetidine methanol the NMR test results of compound 6 are:
- the specific preparation method is: similar to the preparation method of compound 1, except that one of the raw materials used is tert-butyl-4-(2-hydroxyethyl)piperazine-1-carboxylate, and equimolar substitution compound ( 1-Boc-3-azetidine methanol in the preparation method of 1-1), the nuclear magnetic test result of compound 7 is:
- the specific preparation method is: similar to the preparation method of compound 1, except that one of the raw materials used is 1-BOC-4-(3-hydroxypropane)piperazine, and equimolar replaces the preparation method of compound (1-1) 1-Boc-3-azetidine methanol in the 1-Boc-3-azetidine methanol, the NMR test results of compound 8 are:
- the specific preparation method is: similar to the preparation method of compound 1, except that one of the raw materials used is 1-BOC-4-(4-hydroxybutane)piperazine, which is equimolar instead of the preparation of compound (1-1).
- 1-Boc-3-azetidine methanol in the method the nuclear magnetic test results of compound 9 are:
- the specific preparation method is: similar to the preparation method of compound 1, except that one of the raw materials used is 1-BOC-4-(5-hydroxypentane)piperazine, which is equimolar instead of the preparation of compound (1-1).
- 1-Boc-3-azetidine methanol in the method the NMR test results of compound 10 are:
- the specific preparation method is: similar to the preparation method of compound 1, except that one of the raw materials used is 1-BOC-4-(6-hydroxyhexane)piperazine, which is equimolar instead of the preparation of compound (1-1).
- 1-Boc-3-azetidine methanol in the method the NMR test results of compound 11 are:
- the specific preparation method is: similar to the preparation method of compound 1, except that one of the raw materials used is 1-BOC-4-(7-hydroxyheptane)piperazine, which is equimolar instead of the preparation of compound (1-1).
- 1-Boc-3-azetidine methanol in the method the nuclear magnetic test results of compound 12 are:
- the specific preparation method is: similar to the preparation method of compound 1, except that one of the raw materials used is 3,4-methylenephenylboronic acid, and equimolar replaces 3,5 in the preparation method of compound (1-2).
- -Dimethoxybenzeneboronic acid the NMR test results of compound 13 are:
- the specific preparation method is: similar to the preparation method of compound 1, except that one of the raw materials used is benzofuran-2-boronic acid, and equimolar replaces 3,5-dicarbonate in the preparation method of compound (1-2).
- the NMR test results of methoxybenzeneboronic acid, compound 14 are:
- the specific preparation method is: similar to the preparation method of compound 1, the difference is that one of the raw materials used is p-methoxyboronic acid, and equimolar replaces 3,5-dimethoxy in the preparation method of compound (1-2).
- the NMR test results of phenylboronic acid, compound 15 are:
- the specific preparation method is: similar to the preparation method of compound 1, the difference is that one of the raw materials used is 4-acetamidophenylboronic acid, and equimolar replaces 3,5-dimethyl in the preparation method of compound (1-2).
- the NMR test results of oxyphenylboronic acid, compound 16 are:
- the specific preparation method is: similar to the preparation method of compound 1, the difference is that one of the raw materials used is 4-trifluoromethoxybenzeneboronic acid, and equimolar replaces 3,5 in the preparation method of compound (1-2).
- -Dimethoxyphenylboronic acid the NMR test results of compound 17 are:
- the specific preparation method is: similar to the preparation method of compound 1, the difference is that one of the raw materials used is 2-naphthalene boronic acid, and equimolar replaces 3,5-dimethoxy in the preparation method of compound (1-2).
- the NMR test results of phenylboronic acid, compound 18 are:
- the specific preparation method is: similar to the preparation method of compound 1, except that one of the raw materials used is 4-methylnaphthalene boronic acid, and equimolar replaces 3,5-dimethyl in the preparation method of compound (1-2).
- the NMR test results of oxyphenylboronic acid, compound 19 are:
- the specific preparation method is: similar to the preparation method of compound 1, the difference is that one of the raw materials used is 4-bromonaphthalene boronic acid, and equimolar replaces 3,5-dimethoxyl in the preparation method of compound (1-2).
- the NMR test results of phenylboronic acid, compound 20 are:
- the specific preparation method is: similar to the preparation method of compound 1, the difference is that one of the raw materials used is 2,5-dimethoxybenzeneboronic acid, and equimolar replaces 3 in the preparation method of compound (1-2), 5-dimethoxybenzeneboronic acid, the NMR test results of compound 21 are:
- the specific preparation method is: similar to the preparation method of compound 1, except that one of the raw materials used is 3,4-dimethoxybenzeneboronic acid, and equimolar replaces 3 in the preparation method of compound (1-2), 5-Dimethoxybenzeneboronic acid, the NMR test results of compound 22 are:
- the specific preparation method is: similar to the preparation method of compound 1, except that one of the raw materials used is 3,4,5-trimethoxybenzeneboronic acid, and equimolar replaces 3 in the preparation method of compound (1-2).
- 5-dimethoxybenzeneboronic acid the NMR test results of compound 23 are:
- the specific preparation method is: similar to the preparation method of compound 1, the difference is that one of the raw materials used is 3-trifluoromethylbenzeneboronic acid, and equimolar replaces 3,5-
- the NMR test results of dimethoxybenzeneboronic acid, compound 24 are:
- the specific preparation method is: similar to the preparation method of compound 1, the difference is that one of the raw materials used is 3-isopropoxyphenylboronic acid, and equimolar replaces 3,5-
- the NMR test results of dimethoxybenzeneboronic acid, compound 25 are:
- the specific preparation method is: similar to the preparation method of compound 1, the difference is that one of the raw materials used is 3-benzyloxyphenylboronic acid, and equimolar replaces 3,5-dicarbonate in the preparation method of compound (1-2).
- the NMR test results of methoxybenzeneboronic acid, compound 26 are:
- the specific preparation method is: similar to the preparation method of compound 1, except that one of the raw materials used is 2-chloro-5-methoxybenzeneboronic acid, and equimolar replaces 3 in the preparation method of compound (1-2).
- 5-dimethoxybenzeneboronic acid the NMR test results of compound 27 are:
- the specific preparation method is: similar to the preparation method of compound 1, except that one of the raw materials used is p-fluorophenylboronic acid, and equimolar replaces 3,5-dimethoxy in the preparation method of compound (1-2).
- the NMR test results of phenylboronic acid, compound 28 are:
- the specific preparation method is: similar to the preparation method of compound 1, the difference is that one of the raw materials used is 3-fluoro-4-hydroxyphenylboronic acid, and equimolar replaces 3,5 in the preparation method of compound (1-2).
- -Dimethoxybenzeneboronic acid the NMR test results of compound 29 are:
- the specific preparation method is: similar to the preparation method of compound 1, the difference is that one of the raw materials used is 6-methoxynaphthalene-2-boronic acid, and equimolar replaces 3 in the preparation method of compound (1-2), 5-dimethoxybenzeneboronic acid, the NMR test results of compound 30 are:
- the specific preparation method is: similar to the preparation method of compound 1, except that one of the raw materials used is p-nitrophenylboronic acid, and equimolar replaces 3,5-dimethoxyl in the preparation method of compound (1-2).
- the NMR test results of phenylboronic acid, compound 31 are:
- the specific preparation method is: similar to the preparation method of compound 1, except that one of the raw materials used is 3-fluoro-5-methoxybenzeneboronic acid, and equimolar replaces 3 in the preparation method of compound (1-2).
- 5-dimethoxybenzeneboronic acid the NMR test results of compound 31 are:
- the specific preparation method is: similar to the preparation method of compound 1, except that one of the raw materials used is 3,5-difluorophenylboronic acid, and equimolar replaces 3,5-difluorophenylboronic acid in the preparation method of compound (1-2).
- the NMR test results of dimethoxybenzeneboronic acid, compound 33 are:
- the specific preparation method is: similar to the preparation method of compound 1, except that one of the raw materials used is 3,5-ditrifluoromethylbenzeneboronic acid, and equimolar replaces 3 in the preparation method of compound (1-2).
- 5-dimethoxybenzeneboronic acid the NMR test results of compound 34 are:
- the specific preparation method is: similar to the preparation method of compound 1, the difference is that one of the raw materials used is 3-fluoro-5-trifluoromethylbenzeneboronic acid, and equimolar replaces the
- the NMR test results of 3,5-dimethoxybenzeneboronic acid, compound 35 are:
- the specific preparation method is: similar to the preparation method of compound 10, the difference is that one of the raw materials used is 4,4,4-trifluorobutenoic acid, and equimolar replaces propylene in the preparation method of compound (1-3)
- the NMR test results of acid chloride, compound 36 are:
- the specific preparation method is: similar to the preparation method of compound 34, except that one of the raw materials used is 4,4,4-trifluorobutenoic acid, and equimolar replaces propylene in the preparation method of compound (1-3) Acid chloride, the NMR test result of compound 37 is:
- the specific preparation method is: similar to the preparation method of compound 35, except that one of the raw materials used is 4,4,4-trifluorobutenoic acid, and equimolar replaces propylene in the preparation method of compound (1-3)
- the NMR test results of acid chloride, compound 38 are:
- the specific preparation method is: similar to the preparation method of compound 10, the difference is that one of the raw materials used is trans-4-dimethylaminocrotonic acid, and equimolar replaces propylene in the preparation method of compound (1-3)
- the NMR test results of acid chloride, compound 39 are:
- the specific preparation method is: similar to the preparation method of compound 10, the difference is that one of the raw materials used is crotonic acid, and equimolar replaces the acryloyl chloride in the preparation method of compound (1-3), and the NMR test result of compound 40 is :
- the present invention adopts homogeneous time-resolved fluorescence (HIRF) technology to evaluate the inhibitory effect of compounds on four subtypes of FGFR1, 2, 3 and 4.
- HIRF time-resolved fluorescence
- compounds 10 and 36 were selected, and the MTT colorimetric method was used to evaluate the proliferation inhibitory effects of the compounds 10 and 36 on various tumor cells.
- Tumor cells in logarithmic growth phase were collected by trypsinization, resuspended in 1 mL of fresh medium, and then diluted with a small amount, and the number of cells was counted with a hemocytometer.
- tumor cells were seeded into 96-well plates at a density of 3000-5000 cells/well, and then placed in a cell culture incubator for 24 hours. Then, the tumor cells were treated with compounds 10 and 36, and 8 concentrations were set, and three replicate wells were set for each concentration, and the cells were incubated for 96 h.
- MTT solution 5 mg/mL was added to each well, beat and mixed, and then placed in a cell culture incubator for 3-4 hours. After incubation, carefully aspirate the liquid from the well plate, then add 100 ⁇ L of DMSO solution to each well. Set the microplate reader program, measure the absorbance values at 490nm and 570nm respectively, calculate the proliferation inhibition rate of each concentration according to the formula, and finally use Graphpad Prism 7 software for data processing to calculate IC50.
- Example 43 Compounds 10 and 36 inhibit FGF/FGFR and its downstream signaling pathways
- the old medium was aspirated, fresh medium containing compounds 10 and 36 at different concentrations was added, and the cells were incubated in a cell incubator for 12 h. After incubation, aspirate the supernatant, wash three times with pre-cooled 1X PBS solution, thoroughly remove the residual liquid, add 60 ⁇ L of RIPA lysis buffer to each well, gently scrape the cells with a cell scraper, and transfer the lysis buffer to In a 1.5mL EP tube, ice bath for 10min, centrifuge at 14000rpm for 10min, pipette the supernatant into a new 1.5mL EP tube, pipette a small amount for protein content determination, add a corresponding volume of 5X loading buffer to the rest, vortex to mix, 100 °C metal bath for 10min.
- the corresponding loading amount was calculated according to the loading amount of 30 ⁇ g protein per well.
- Use 8% SDS-PAGE gel electrophoresis to separate the protein transfer the separated protein to PDVF membrane, stain with Ponceau red, cut the PDVF membrane containing the protein according to the molecular weight of the target protein, wash the Ponceau red with 1X TBST solution, 5% nonfat dry milk was blocked for 30 min. Wash three times with 1X TBST solution, put the PDVF membrane containing the target protein band into the incubation box, add the corresponding primary antibody incubation solution, and incubate at 4°C overnight.
- compounds 10 and 36 not only significantly inhibited the phosphorylation of FGFR1 in NCI-H1581 cells and FGFR2 in SNU-16 cells, but also inhibited the activation of downstream PLC ⁇ , AKT and ERK in a dose-dependent manner. Collectively, compounds 10 and 36 can strongly inhibit FGF/FGFR and downstream signaling pathways in vitro.
- Example 44 Compounds 10 and 36 significantly inhibit tumor growth in mice
- a mouse subcutaneous xenograft tumor model was established with human lung squamous cell carcinoma cells NCI-H1581 with high FGFR1 expression.
- mice When the tumor volume grows to 50-100mm , the mice are randomly divided into three groups (control group, 50mg/kg, 100mg/kg), 6 mice in each group, compound 10 is administered orally every day, compound 36 is intraperitoneally every day After injection, the tumor volume and mouse body weight were measured. After 26 days of administration, the mice were treated, and the tumor tissue was dissected and fixed in formalin solution for use.
- the present inventors optimized and discovered novel derivatives of 2H-pyrazolo[3,4-d]pyrimidines, compounds 10 and 36, as potent and selective inhibitors against FGFR1, FGFR2 and FGFR3, characterized irreversible binding.
- the lead compound not only inhibited FGF/FGFR and its downstream signaling pathways at low concentrations, but also showed significant anti-proliferative effects on NCI-H1581 cancer cell line both in vitro and in vivo.
- compounds 10 and 36 show low toxicity and have good PK properties and are currently being identified as potential drug candidates.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (20)
- 如权利要求1所述的化合物或其在药学上可接受的盐,其特征在于,所述R为H、CF 3、(CH 3) 2NCH 2或CH 3。
- 权利要求1~5任一项所述的化合物、其药学上可接受的盐在制备肿瘤细胞增殖抑制剂中的应用,其特征在于,所述肿瘤细胞为具有FGFR异常的相关的肿瘤细胞。
- 如权利要求8所述的应用,其特征在于,所述肿瘤细胞包括NCI-H1581、SNU-16。
- 权利要求1~5任一项所述的化合物、其药学上可接受的盐在阻断肿瘤细胞中FGF/FGFR信号通路中的应用,其特征在于,所述肿瘤细胞为具有FGFR异常的相关的肿瘤细胞。
- 如权利要求10所述的应用,其特征在于,所述肿瘤细胞包括NCI-H1581或SNU-16。
- 一种含有权利要求1~5任一项所述的化合物、其药学上可接受的盐的药物组合物,其特征在于,包括一种或多种药学上可接受的赋形剂;所述药物组合物的剂型为药学上可接受的任一剂型。
- 权利要求1~5任一项所述的化合物、其药学上可接受的盐或权利要求12所述的药物组合物在制备治疗和/或预防癌症的药物中的应用。
- 根据权利要求9所述的应用,其特征在于,所述癌症为具有FGFR异常的相关癌症。
- 权利要求12所述的药物组合物在用于制备作为不可逆的泛成纤维细胞生长因子受体抑制剂中的应用。
- 一种治疗癌症的方法,其特征在于,包括以下步骤:通过口服或者腹腔注射的方式,将治疗癌症的药物对患者进行给药;所述治疗癌症的药物包括权利要求1~5任一项所述的化合物、其药学上可接受的盐。
- 如权利要求16所述的方法,其特征在于,所述治疗癌症的药物包括化合物10或化合物36。
- 如权利要求17所述的方法,其特征在于,所述给药的剂量为50mg/kg或100mg/kg;所述给药的剂量以所述化合物10或化合物36的用量计。
- 如权利要求17或18所述的方法,其特征在于,当所述治疗癌症的药物包括所述化合物10时,所述给药的方式为口服。
- 如权利要求17或18所述的方法,其特征在于,当所述治疗癌症的药物包括所述化合物36时,所述给药的方式为腹腔注射。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022554428A JP7525630B2 (ja) | 2020-12-16 | 2021-09-24 | 化合物とその調製方法及びそれらの抗がん剤の調製における使用 |
KR1020227032105A KR20220142500A (ko) | 2020-12-16 | 2021-09-24 | 화합물 및 그 제조방법과 이의 항암치료약물의 제조에서의 응용 |
EP21905192.7A EP4116302A4 (en) | 2020-12-16 | 2021-09-24 | COMPOUND AND METHOD OF PRODUCTION THEREOF AND APPLICATION THEREOF IN THE PRODUCTION OF A THERAPEUTIC ANTICANCER DRUG |
CA3196572A CA3196572A1 (en) | 2020-12-16 | 2021-09-24 | Compound and preparation method thereof and application thereof in preparation of therapeutic anti-cancer drug |
AU2021398802A AU2021398802B2 (en) | 2020-12-16 | 2021-09-24 | Compound and preparation method thereof and application thereof in preparation of therapeutic anti-cancer drug |
US17/915,817 US20230159537A1 (en) | 2020-12-16 | 2021-09-24 | Compound, preparation method thereof, and use thereof in preparation of anti-cancer drug |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011483614.1A CN112574216B (zh) | 2020-12-16 | 2020-12-16 | 一种化合物及其制备方法以及其在制备治疗抗癌药物中的应用 |
CN202011483614.1 | 2020-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022127261A1 true WO2022127261A1 (zh) | 2022-06-23 |
Family
ID=75135393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/120046 WO2022127261A1 (zh) | 2020-12-16 | 2021-09-24 | 一种化合物及其制备方法以及其在制备治疗抗癌药物中的应用 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20230159537A1 (zh) |
EP (1) | EP4116302A4 (zh) |
JP (1) | JP7525630B2 (zh) |
KR (1) | KR20220142500A (zh) |
CN (1) | CN112574216B (zh) |
AU (1) | AU2021398802B2 (zh) |
CA (1) | CA3196572A1 (zh) |
WO (1) | WO2022127261A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112574216B (zh) * | 2020-12-16 | 2022-03-08 | 天津济坤医药科技有限公司 | 一种化合物及其制备方法以及其在制备治疗抗癌药物中的应用 |
CN113264937B (zh) * | 2021-06-08 | 2022-11-29 | 南开大学 | 一种4-氨基吡唑并[3,4-d]嘧啶衍生物及其应用 |
CN118414335A (zh) * | 2021-11-15 | 2024-07-30 | 微境生物医药科技(上海)有限公司 | 作为Src抑制剂的化合物 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013102059A1 (en) * | 2011-12-30 | 2013-07-04 | Pharmacyclics, Inc. | Pyrazolo [3, 4-d] pyrimidine and pyrrolo [2, 3-d] pyrimidine compounds as kinase inhibitors |
CN106928231A (zh) * | 2015-12-31 | 2017-07-07 | 合肥中科普瑞昇生物医药科技有限公司 | 一类新型的egfr野生型和突变型的激酶抑制剂 |
CN107513068A (zh) * | 2016-06-16 | 2017-12-26 | 中国科学院上海药物研究所 | 一种具有fgfr抑制活性的新型化合物及其制备和应用 |
WO2019034075A1 (zh) * | 2017-08-15 | 2019-02-21 | 南京明德新药研发股份有限公司 | Fgfr和egfr抑制剂 |
CN109970740A (zh) * | 2017-12-27 | 2019-07-05 | 广东众生药业股份有限公司 | 4-氨基-嘧啶并氮杂环衍生物及其制备方法和用途 |
CN112574216A (zh) * | 2020-12-16 | 2021-03-30 | 天津济坤医药科技有限公司 | 一种化合物及其制备方法以及其在制备治疗抗癌药物中的应用 |
CN113264937A (zh) * | 2021-06-08 | 2021-08-17 | 南开大学 | 一种4-氨基吡唑并[3,4-d]嘧啶衍生物及其应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2201840B1 (en) * | 2006-09-22 | 2011-11-02 | Pharmacyclics, Inc. | Inhibitors of Bruton's Tyrosine Kinase |
EP2954900A1 (en) * | 2007-03-28 | 2015-12-16 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
CN107417687A (zh) * | 2016-05-24 | 2017-12-01 | 中国科学院上海药物研究所 | 五元杂环并[3,4‑d]哒嗪酮类化合物、其制备方法、药物组合物及其应用 |
CN109369654A (zh) * | 2018-11-20 | 2019-02-22 | 山东大学 | 1,3-二取代-4-氨基吡唑并嘧啶类化合物及其制备方法和应用 |
CN111018865B (zh) * | 2019-10-17 | 2021-01-15 | 山东大学 | 1-取代苄基吡唑并嘧啶衍生物及其制备方法与应用 |
-
2020
- 2020-12-16 CN CN202011483614.1A patent/CN112574216B/zh active Active
-
2021
- 2021-09-24 KR KR1020227032105A patent/KR20220142500A/ko active Search and Examination
- 2021-09-24 US US17/915,817 patent/US20230159537A1/en active Pending
- 2021-09-24 CA CA3196572A patent/CA3196572A1/en active Pending
- 2021-09-24 EP EP21905192.7A patent/EP4116302A4/en active Pending
- 2021-09-24 WO PCT/CN2021/120046 patent/WO2022127261A1/zh active Application Filing
- 2021-09-24 AU AU2021398802A patent/AU2021398802B2/en active Active
- 2021-09-24 JP JP2022554428A patent/JP7525630B2/ja active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013102059A1 (en) * | 2011-12-30 | 2013-07-04 | Pharmacyclics, Inc. | Pyrazolo [3, 4-d] pyrimidine and pyrrolo [2, 3-d] pyrimidine compounds as kinase inhibitors |
CN106928231A (zh) * | 2015-12-31 | 2017-07-07 | 合肥中科普瑞昇生物医药科技有限公司 | 一类新型的egfr野生型和突变型的激酶抑制剂 |
CN107513068A (zh) * | 2016-06-16 | 2017-12-26 | 中国科学院上海药物研究所 | 一种具有fgfr抑制活性的新型化合物及其制备和应用 |
WO2019034075A1 (zh) * | 2017-08-15 | 2019-02-21 | 南京明德新药研发股份有限公司 | Fgfr和egfr抑制剂 |
CN109970740A (zh) * | 2017-12-27 | 2019-07-05 | 广东众生药业股份有限公司 | 4-氨基-嘧啶并氮杂环衍生物及其制备方法和用途 |
CN112574216A (zh) * | 2020-12-16 | 2021-03-30 | 天津济坤医药科技有限公司 | 一种化合物及其制备方法以及其在制备治疗抗癌药物中的应用 |
CN113264937A (zh) * | 2021-06-08 | 2021-08-17 | 南开大学 | 一种4-氨基吡唑并[3,4-d]嘧啶衍生物及其应用 |
Non-Patent Citations (23)
Title |
---|
BABINA, I. S.TURNER, N. C.: "Advances and challenges in targeting FGFR signalling in cancer", NAT. REV. CANCER, vol. 17, 2017, pages 318 - 332 |
BELLO, E.COLELLA, G.SCARLATO, V.OLIVA, P.BERNDT, A.VALBUSA, G.SERRA, S. C.D'INCALCI, M.CAVALLETTI, E.GIAVAZZI, R.: "E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models", CANCER RES, vol. 71, 2011, pages 1396 - 1405, XP002716768, DOI: 10.1158/0008-5472.CAN-10-2700 |
BRAMELD, K. A.; OWENS, T. D.; VERNER, E.; VENETSANAKOS, E.; BRADSHAW, J. M.; PHAN, V. T.; TAM, D.; LEUNG, K.; SHU, J.; LASTANT, J.: "Discovery of the irreversible covalent FGFR inhibitor 8-(3-(4-acryloylpiperazin-l-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)p yrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the treatment of solid tumors", J. MED. CHEM., vol. 60, 2017, pages 6516 - 6527, XP055675966, DOI: 10.1021/acs.jmedchem.7b00360 |
BROWN, W. S.TAN, L.SMITH, A.GRAY, N. S.WENDT, M. K.: "Covalent targeting of fibroblast growth factor receptor inhibits metastatic breast cancer", MOL. CANCER THER., vol. 15, 2016, pages 2096 - 2106 |
CARTER, E. P.FEARON, A. E.GROSE, R. P.: "Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction", TRENDS CELL BIOL, vol. 25, 2015, pages 221 - 233 |
DIECI, M. V.ARNEDOS, M.ANDRE, F.SORIA, J. C.: "Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives", CANCER DISCOVERY, vol. 3, 2013, pages 264 - 279, XP055127772, DOI: 10.1158/2159-8290.CD-12-0362 |
GAVINE, P. R.MOONEY, L.KILGOUR, E.THOMAS, A. P.AL-KADHIMI, K.BECK, S.ROONEY, C.COLEMAN, T.BAKER, D.MELLOR, M. J.: "AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family", CANCER RES, vol. 72, 2012, pages 2045 - 2056, XP055065340, DOI: 10.1158/0008-5472.CAN-11-3034 |
GOZGIT, J. M.WONG, M. J.MORAN, L.WARDWELL, S.MOHEMMAD, Q. K.NARASIMHAN, N. I.SHAKESPEARE, W. C.WANG, F.CLACKSON, T.RIVERA, V. M.: "Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models", MOL. CANCER THER., vol. 11, 2012, pages 690 - 699, XP055065380, DOI: 10.1158/1535-7163.MCT-11-0450 |
GUAGNANO, V.FURET, P.SPANKA, C.BORDAS, V.LE DOUGET, M.STAMM, C.BRUEGGEN, J.JENSEN, M. R.SCHNELL, C.SCHMID, H.: "Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-16-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin -4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase", J. MED. CHEM., vol. 54, 2011, pages 7066 - 7083, XP002689272, DOI: 10.1021/jm2006222 |
HAGEL, M.MIDUTURU, C.SHEETS, M.RUBIN, N.WENG, W.STRANSKY, N.BIFULCO, N.KIM, J. L.HODOUS, B.BROOIJMANS, N.: "First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway", CANCER DISCOVERY, vol. 5, 2015, pages 424 - 437, XP055857952, DOI: 10.1158/2159-8290.CD-14-1029 |
HE, LINHONG ET AL.: "Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of arthritis", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 145, 28 December 2017 (2017-12-28), XP085414790, DOI: 10.1016/j.ejmech.2017.12.079 * |
LI, X.GUISE, C. P.TAGHIPOURAN, R.YOSAATMADJA, Y.ASHOORZADEH, A.PAIK, W.SQUIRE, C. J.JIANG, S.LUO, J.XU, Y: "2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors", EUR. J. MED. CHEM., vol. 135, 2017, pages 531 - 543, XP085047556, DOI: 10.1016/j.ejmech.2017.04.049 |
PERERA, T. P. S.JOVCHEVA, E.MEVELLEC, L.VIALARD, J.DE LANGE, D.VERHULST, T.PAULUSSEN, C.VAN DE VEN, K.KING, P.FREYNE, E.: "Discovery and pharmacological characterization of JNJ-42756493 (erdafitinib), a functionally selective small-molecule FGFR family inhibitor", MOL. CANCER THER., vol. 16, 2017, pages 1010 - 1020 |
RENHOWE, P. A.PECCHI, S.SHAFER, C. M.MACHAJEWSKI, T. D.JAZAN, E. M.TAYLOR, C.ANTONIOS-MCCREA, W.MCBRIDE, C. M.FRAZIER, K.WIESMANN,: "Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors", J. MED. CHEM., vol. 52, 2009, pages 278 - 292 |
ROTH, G. J.HECKEL, A.COLBATZKY, F.HANDSCHUH, S.KLEY, J.LEHMANN-LINTZ, T.LOTZ, R.TONTSCH-GRUNT, U.WALTER, R.HILBERG, F.: "Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120", J. MED. CHEM., vol. 52, 2009, pages 4466 - 4480 |
See also references of EP4116302A4 |
TAN, L.WANG, J.TANIZAKI, J.HUANG, Z.AREF, A. R.RUSAN, M.ZHU, S. J.ZHANG, Y.ERCAN, D.LIAO, R. G.: "Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors", PROC. NATL. ACAD. SCI. U. S. A., vol. 111, 2014, pages E4869 - E4877, XP055532820, DOI: 10.1073/pnas.1403438111 |
TOUAT, M.ILEANA E.POSTEL-VINA S.ANDRE, F.SORIA J. C.: "Targeting FGFR signaling in cancer", CLIN. CANCER RES., vol. 21, 2015, pages 2684 - 2694 |
TURNER, N.GROSE, R.: "Fibroblast growth factor signalling: from development to cancer", NAT. REV. CANCER, vol. 10, 2010, pages 116 - 129 |
WANG, Y.DAI, Y.WU, X.LI, F.LIU, B.LI, C.LIU, Q.ZHOU, Y.WANG, B.ZHU, M.: "Discovery and Development of a Series of Pyrazolo[3,4- d]pyridazinone Compounds as the Novel Covalent Fibroblast Growth Factor Receptor Inhibitors by the Rational Drug Design", J. MED. CHEM., vol. 62, 2019, pages 7473 - 7488 |
WANG, Y.LI, L.FAN, J.DAI, Y.JIANG, A.GENG, M.AI, J.DUAN, W.: "Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors", J. MED. CHEM., vol. 61, 2018, pages 9085 - 9104, XP055523638, DOI: 10.1021/acs.jmedchem.7b01843 |
ZHAO, G.LI, W. Y.CHEN, D.HENRY, J. R.LI, H. Y.CHEN, Z.ZIA-EBRAHIMI, M.BLOEM, L.ZHAI, Y.HUSS, K.: "A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models", MOL. CANCER THER., vol. 10, 2011, pages 2200 - 2210, XP055160880, DOI: 10.1158/1535-7163.MCT-11-0306 |
ZHOU, W.HUR, W.MCDERMOTT, U.DUTT, A.XIAN, W.FICARRO, S. B.ZHANG, J.SHARMA, S. V.BRUGGE, J.MEYERSON, M.: "A structure-guided approach to creating covalent FGFR inhibitors", CHEM. BIOL., vol. 17, 2010, pages 285 - 295, XP026984442 |
Also Published As
Publication number | Publication date |
---|---|
JP2023516483A (ja) | 2023-04-19 |
CA3196572A1 (en) | 2022-06-23 |
EP4116302A4 (en) | 2023-10-11 |
CN112574216A (zh) | 2021-03-30 |
AU2021398802B2 (en) | 2024-06-20 |
AU2021398802A1 (en) | 2023-05-11 |
KR20220142500A (ko) | 2022-10-21 |
EP4116302A1 (en) | 2023-01-11 |
US20230159537A1 (en) | 2023-05-25 |
JP7525630B2 (ja) | 2024-07-30 |
CN112574216B (zh) | 2022-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022127261A1 (zh) | 一种化合物及其制备方法以及其在制备治疗抗癌药物中的应用 | |
WO2018121228A1 (zh) | 一种具有axl抑制活性的化合物及其制备和应用 | |
TWI334417B (en) | Azaindoles | |
EP2850082B1 (en) | 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido(2,3-d)pyrimidin-6-yl)phenyl)urea as Raf kinase inhibitor for the treatment of cancer | |
EP1963316A2 (en) | Pyrazolo[1,5-a]pyridine-3-carboxylic acids as ephb and vegfr2 kinase inhibitors | |
CN102131390A (zh) | 三唑并吡啶jak抑制剂化合物和方法 | |
CN104797581A (zh) | 杂芳基炔烃化合物及其应用 | |
JP6372722B2 (ja) | 新規化学化合物(誘導体)及び腫瘍性疾患の処置のためのそれらの適用 | |
WO2022217821A1 (zh) | 炔苯基苯酰胺类化合物及其应用 | |
EP3858833A1 (en) | Aminonordecane derivative, and preparation method therefor and application thereof | |
WO2015058661A1 (zh) | Bcr-abl激酶抑制剂及其应用 | |
EP3661935A1 (en) | Substituted pyrazolopyrimidines useful as kinases inhibitors | |
WO2023279938A1 (zh) | 2,6,8-多取代咪唑并[1,2-a]吡嗪及其合成方法和应用 | |
CN115768761A (zh) | 新颖苯并咪唑衍生物 | |
Li et al. | Design, synthesis and biological evaluation of a new class of 7H-pyrrolo [2, 3-d] pyrimidine derivatives as Mps1 inhibitors for the treatment of breast cancer | |
WO2015120737A1 (zh) | 取代的吡啶并嘧啶化合物及其制备方法和应用 | |
CN110467616B (zh) | 含杂芳基取代哒嗪酮结构的三唑并吡嗪类化合物的制备及应用 | |
Wu et al. | Design, synthesis and biological evaluation of a series of novel pyrrolo [2, 3-d] pyrimidin/pyrazolo [3, 4-d] pyrimidin-4-amine derivatives as FGFRs-dominant multi-target receptor tyrosine kinase inhibitors for the treatment of gastric cancer | |
WO2023036252A1 (zh) | 吡咯并嘧啶类或吡咯并吡啶类衍生物及其医药用途 | |
CN113416181B (zh) | 喹唑啉类衍生物及其用途 | |
CN109384788A (zh) | 嘌呤系列衍生物及其制备方法和用途 | |
CN110407839B (zh) | 含杂芳基酰胺结构的三唑并杂环类化合物的制备及应用 | |
RU2821945C1 (ru) | Соединение, способ его получения и его применение для получения противоракового лекарственного средства | |
EP2800566B1 (en) | Therapeutic use of imidazopyridine derivatives | |
CN114181217B (zh) | 吡唑并[1,5-a][1,3,5]三嗪衍生物及其盐和在制备抗癌药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21905192 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022554428 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20227032105 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2021905192 Country of ref document: EP Effective date: 20221003 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202217057850 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 3196572 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021398802 Country of ref document: AU Date of ref document: 20210924 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023008739 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112023008739 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230508 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |